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Abstract
To investigate the effect and the safety of Adenosine triphosphate disodium 
hydrate (ATP-2Na) for asthenopia. 40 subjects [35 females and 5 males, 25~87 years 
old (average: 62.5 years old)] with asthenopia ingested 200~300 mg/day ATP-2Na 
for 3 months. Before and after 1 and 3 months ingestion, subjects completed a 
questionnaire to determine their asthenopia symptom and fatigue symptom by 
visual analog scale (VAS). The scores were compared between before and after 
ingestion. 31 subjects completed a questionnaire for 1 month. The scores of asthe-
nopia symptom before ingestion, 1 and 3 months were 4.05 ± 3.22, 2.67 ± 2.19 and 
2.41 ± 2.16, respectively. The scores of fatigue symptom were 4.76 ± 3.05, 3.08 ± 2.93 
and 3.10 ± 3.19, respectively. Both scores were significantly decreased (p < 0.005) 
at 1 month compared before ingestion. Three subjects had side effects (diarrhea 
for two, nausea for one), and all subjects improved by oral discontinuation. These 
results suggest that ATP-2Na is relatively early effective in improving asthenopia 
and accompanying fatigue symptoms.
Keywords: adenosine triphosphate disodium hydrate(ATP-2Na), asthenopia 
symptom, fatigue symptom, visual analog scale (VAS), 3 months
1. Introduction
Recent years, patients with asthenopia increased, because many people are 
engaged in visual display terminal (VDT) work and are using a portable terminal 
for example smartphone. The causes of asthenopia are dry eye [1, 2], lack of cor-
rection for hyperopia or presbyopia, overcorrection for myopia by contact lens or 
glasses for example. Eye treatment for these causes does not improve asthenopia in 
some cases. On the other hand, patients with asthenopia sometimes complain of 
systemic symptoms such as headache, stiff shoulder, nausea and fatigue. Symptoms 
by VDT work are serious problems in Japan, so Ministry of Health, Labor and 
Welfare established guideline for Occupational Health Environmental Management 
in 2002 [3]. In this guideline, at first, improvement of environment for VDT is 
necessary, and in serious cases patients should see clinical ophthalmologists. In 
questionnaire results in 2003 in Japan, many ophthalmologists prescribe glasses 
for near work or tear drop or Vitamin B12 eye drop to reduce asthenopia from VDT 
work [4].
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Adenosine triphosphate disodium hydrate (ATP-2Na) is internal medicine 
which approved for asthenopia from the results of multicenter clinical researches 
or double blind clinical researches in 1970~1990 in Japan [5–7]. In this study, we 
researched the effect and the safety of ATP-2Na for present asthenopia.
2. Subjects and methods
2.1 Subjects
Subjects were patients with asthenopia in Kyoto Prefectural University of 
Medicine facilities in 2012~2014. We selected patients who had asthenopia symp-
toms, regardless of causes such as dry eye or inappropriate glasses. Subjects were 40 
patients (35 females and 5 males), and 25~87 years old (average age: 62.5 years old).
2.2 Methods
Two or three times per day, subjects ingested Adetphos Kowa Granule 10% 
which is clinical medicine containing 100 mg of ATP-2Na. Before and after 1 and 3 
Table 1. 
Visual analog scale (VAS).
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months ingestion, subjects completed a questionnaire to determine their asthe-
nopia symptom and fatigue symptom by visual analog scale (VAS) [8] (Table 1). 
In VAS scale, 0 is the best evaluated result and 10 is the worst evaluated result. 
Questionnaire items were 10 items; 5 items about eye symptoms (feeling of 
oppression of the eyes, pain in the back of the eyes, tough to open eyes, blurred 
vision, sense of heat of eyes), 3 items about systemic symptoms (headache, stiff 
shoulder, fatigue), and 2 items about mental symptoms (depressed feeling, no 
concentration feeling). The scores were compared between before and after 
ingestion.
In addition, the scores were compared about the background factors before 
administration. Researched background factors were gender, age, internal dose per 
body weight, whether or not other eye diseases, whether or not of using eye drop 
for asthenopia, and scores before ingestion. Within this study, subjects continued 
all drugs prescribed before the administration.
2.3 Statistical analysis
Paired t test was used to compare the change of scores between before and 
after ingestion. In analysis of background factors, student’s t test was used the 
changes through 3 months. In both analysis, p < 0.05 was considered statistically 
significant.
3. Results
3.1 Subject characteristics
In 40 initial subjects, 33 subjects visited hospital at 1 month, and these subjects 
were targeted for evaluation of safety. In 33 subjects, one subject discontinued the 
ingestion because of diarrhea within 1 month, one refused to describe the ques-
tionnaire. 31 subjects completed a questionnaire for 1 month and were targeted 
for effect evaluation. Age distribution of 31 subjects (26 females, 5 males) was 
25–87 years old, average age was 64.4 years old. Background factors are presented 
in Table 2. Average score of eye symptom in group with diabetes was larger than 
that in group without diabetes (p < 0.01). Average score of systemic symptom in 
group 65y younger was larger than that in group 65y older (p < 0.05). 26 subjects 
completed a questionnaire for 3 months.
3.2 Effect evaluations
3.2.1 Scores in each symptom
The scores about eye symptom before ingestion, 1 month, 3 months were 
4.05 ± 3.22, 2.67 ± 2.19, and 2.41 ± 2.16, respectively. The scores were significantly 
decreased at 1 and 3 months (both p < 0.005, Figure 1). Among the symptoms 
about eye, the scores of “blurred vision” were no different between before and after 
(Figure 2). The scores about systemic symptom (average scores; before ingestion: 
4.76 ± 3.05, 1 month: 3.08 ± 2.93, and 3 months: 3.13 ± 3.18) significantly decreased 
(p < 0.005). Similarly, the scores about mental symptom (average scores; before 
ingestion: 4.41 ± 3.46, 1 month: 2.97 ± 2.63, and 3 months: 3.10 ± 3.19) significantly 
decreased (p < 0.005).
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Figure 1. 
Transition of scores of each symptom. Mean score of each symptom (5 eye symptoms, 3 systemic symptoms, 
2 mental symptoms) before and 1, 3 months after ingestion. The scores were significantly decreased at 1 and 
3 months (both p < 0.005) compared before ingestion. This result means that ingestion of ATP-2Na relatively 
early improved systemic symptoms and mental symptoms as well as eye symptoms.
Table 2. 
Comparison of baseline VAS scores between each groups classified by baseline characteristics (n = 31).
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Figure 2. 
Transition of scores of each detail symptom. Score of each detail symptoms at before, 1 month and 3 months 
after ingestion. Among the symptoms about eye, the scores of “blurred vision” were no different between 
before and after. This result means that the cause of “blurred vision” may be not only due to abnormality in 
accommodation but also due to cataract et al.
Table 3. 
Comparison of change of scores between each groups classified by background factor.
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3.2.2 Comparison about the background factors
There was no difference among groups regarding the background factors about 
gender, age, whether or not other eye diseases, and whether or not of using eye drop for 
asthenopia (Table 3). The larger of initial scores improve larger effect in any symptoms.
3.3 Safety evaluations
Among 33 all subjects, 3 subjects had side effect. 1 subject feel nausea and 2 had 
diarrhea. There was no relation between subjects with side effect and internal dose 
per body weight or other background factors. And all subjects improved by oral 
discontinuation.
4. Discussions
In this study, regardless the causes, asthenopia symptoms improved with inges-
tion of ATP-2Na. And the systemic symptoms (headache, stiff shoulder, fatigue) 
caused by asthenopia improved, as well as the mental symptoms (depressed feeling 
or no concentration feeling).
Asthenopia symptoms from extremely strong eye fatigue cannot improve with 
rest. In report by Suzumura, the cause of asthenopia was categorized into three factors 
(external environmental factors, ophthalmologic factors, and internal /mental factors), 
and asthenopia symptoms got worse by collapse of balance between these three factors 
[9]. In this study, subjects were enrolled by symptoms. We did not research a cause 
of asthenopia symptoms. Ninety-two percent of subjects had systemic symptoms or 
mental symptoms. It is possible that the balance of several factors collapsed in enrolled 
subjects in this study. The more severe the symptoms before ingestion, the stronger 
the improvement effect was confirmed. Severe symptoms that caused a vicious circle 
related by various systemic/mental symptoms, possibly improved better than weak 
symptoms. ATP-2Na increases the blood flow in vertebrae and common carotid artery. 
For the reason, it is suggested that increased blood flow in ciliary body muscle stabi-
lized accommodation, and increased blood flow in vertebrae improved symptoms such 
as stiff shoulder. In our study, asthenopia symptoms of subjects who were administered 
nerve stimulants such as Vitamin B12 improved. Then it is clear that ATP-2Na exerts the 
effect depending on the mechanism different from Vitamin preparations.
Several studies reported that improvement of accommodation by ATP-2Na was 
confirmed by examination such as near point meter or accommodo-polyrecorder 
[5–7]. In these studies, enrolled patients were 20~50 years old whose accommoda-
tion was not lost. But from our study ATP-2Na is effective for asthenopia in patients 
over 65 years old as same as in patients under 65 years old. However, ATP-2Na was 
not effective for blurred vision symptom. It is suggested that blurred vision symp-
tom related several factors for example accommodative dysfunction or cataract. It 
is difficult to detect the abnormality in accommodation by traditional examination 
because of presbyopia. Kajita et al. reported that change of pupil diameter could 
detect ciliary muscle abnormality as objective findings of asthenopia [10]. It is 
thought that asthenopia of senior patients is possibly related to imbalance in ciliary 
muscle [11]. Asthenopia in younger subjects is possibly related to accommodative 
convulsion, on the other hands, asthenopia in older subjects is possibly related to 
accommodative semi-dysfunction [12]. Blood flow increase by ATP-2Na was effec-
tive for asthenopia symptoms from each mechanism.
Among 33 all subjects, 3 subjects had side effect (nausea for 1 and diarrhea 
for 2). All subjects improved from side effect by discontinuation of ingestion. In 
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this study, enrolled subjects were senior patients whose gastrointestinal function 
were slightly impaired, and side effect occurred because of pharmacological action 
of ATP-2Na that increases the gastrointestinal blood flow and that increases the 
gastrointestinal functions. Side effect occurrence rate was not difference among 
background factors in this study. However, it is considered better for safety that 
senior patient whose BMI is low level and whose gastrointestinal function is slightly 
impaired, ingests 200mg/day of ATP-2Na instead of 300mg/day. It is described in 
the package insert and need to explain to the patient.
Some limitations of this report need to be considered. First, this study sets no 
control group, because the effect of ATP-2Na revealed by double blind control study 
in previous studies. Second this study is based on subjective findings only. It is neces-
sary to evaluate the objective findings from examinations as an index of asthenopia.
Even in present day where causes of asthenopia have diversified, ATP-2Na improved 
asthenopia symptoms relatively early in adult cases involving senior patients, moreover, 
ATP-2Na improved systemic/mental symptoms derived from asthenopia. Naturally, 
in the cases related presbyopia or VDT work, it is important to prescribe near glasses 
considering ages, working distance and refractive error. Moreover, this study evaluates 
ATP-2Na is one of effective treatment for asthenopia with systemic/mental symptoms.
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